Pharmaceutical industry in China

Insights on the Musculoskeletal Disorders Drugs Global Market to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:43pm

Combination therapy involves use of more than one medication or drug to treat a disease.

Key Points: 
  • Combination therapy involves use of more than one medication or drug to treat a disease.
  • These changes are related to data protection such as the European Union's General Data Protection Regulation (GDPR), changes to drug approval procedures and other regulatory changes.
  • The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period.
  • This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period.\n"

Global Central Nervous System Drugs Market Report (2021 to 2030) - COVID-19 Impact and Recovery - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:35pm

Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.

Key Points: 
  • Asia Pacific was the second largest region accounting for 22% of the global central nervous system drugs market.
  • Africa was the smallest region in the global central nervous system drugs market.\nMany central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality.
  • In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson's and Alzheimer's diseases.\nThe central nervous system drugs market was mainly driven by rapid growth in emerging markets in the historic period.
  • Thus, strong economic growth boosted the demand for central nervous system drugs and this drove the market during the historic period.\n"

Blow-Fill-Seal Technology Market Size, Share & Analysis 2020-2028: Rise in Demand from Healthcare and Pharmaceutical Sectors to Prevent Contamination - ResearchAndMarkets.com

Thursday, May 6, 2021 - 3:16pm

b'The "Blow-Fill-Seal Technology Market Size, Share & Analysis, By Product, By Raw Material, And By End-Use, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global blow-fill-seal technology market size is expected to reach USD 499.3 Million in 2028, and register a CAGR of 5.20% during the forecast period.\nConstantly growing pharmaceuticals company and rising need for a technique to prevent potential extraneous contamination is a key factor driving market revenue growth.

Key Points: 
  • b'The "Blow-Fill-Seal Technology Market Size, Share & Analysis, By Product, By Raw Material, And By End-Use, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global blow-fill-seal technology market size is expected to reach USD 499.3 Million in 2028, and register a CAGR of 5.20% during the forecast period.\nConstantly growing pharmaceuticals company and rising need for a technique to prevent potential extraneous contamination is a key factor driving market revenue growth.
  • Increasing investments for constant advancements in Blow-Fill-Seal (BFS) technology.\nGrowing awareness regarding prominent advantage offered by blow-fill-seal technique such as sterile and hygienic solution for dispersing products and sealing containers without or minimal human intervention in the fill/finish process among manufacturers in food and beverage, and pharmaceutical industries is a major factor driving market growth.
  • This factor could hamper demand for BFS technology and hamper market growth to some extent.\nSome Key Findings From the Report:\nAmong the product type segments, the bottles segment accounted for significantly high revenue share in the global market in 2020, as bottles are light-in-weight as compared to other options and are easily portable.\nAmong the raw material segments, the Polyvinylchloride (PVC) segment accounted for significant revenue share in 2020.
  • The Polyethylene (PE) segment is projected to register the highest CAGR during the forecast period.\nAmong the end-use segments, the pharmaceutical segment accounted for major revenue share in the global market in 2020, and is expected to register considerably high CAGR during the forecast period.

ITM Establishes Subsidiary in Shanghai to Accelerate Introduction of Its Precision Oncology Portfolio in China

Thursday, May 6, 2021 - 6:00am

b"ITM AG , a leading radiopharmaceutical company, today announced the establishment of a Chinese subsidiary, ITM (Shanghai) Precision Medical Co., Ltd., in Shanghai, China.

Key Points: 
  • b"ITM AG , a leading radiopharmaceutical company, today announced the establishment of a Chinese subsidiary, ITM (Shanghai) Precision Medical Co., Ltd., in Shanghai, China.
  • The new subsidiary will be part of the ITM Group as a wholly foreign-owned entity (WFOE) to further expand ITM\xe2\x80\x99s growing operations in China, which is a key emerging market for novel radiomolecular precision oncology.
  • The ITM Shanghai team will especially focus on expanding and accelerating clinical development, regulatory filings and access of targeted therapeutic and diagnostic radiopharmaceuticals for Chinese patients.
  • We are proud that we have been able to play a part in laying the foundation for radiomolecular precision oncology in China over the past decade.

Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock

Wednesday, May 5, 2021 - 9:03pm

Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries.

Key Points: 
  • Harrow Health also holds large equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries.
  • Harrow Health also owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals.
  • For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .\nThis press release contains \xe2\x80\x9cforward-looking statements\xe2\x80\x9d within the meaning of the U.S.
  • Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made.

January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors

Wednesday, May 5, 2021 - 6:00pm

b'SAN DIEGO, May 5, 2021 /PRNewswire-PRWeb/ --Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020.

Key Points: 
  • b'SAN DIEGO, May 5, 2021 /PRNewswire-PRWeb/ --Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020.
  • Dr. Grint has also served in senior management roles at Cerexa, Forest Laboratories, Kalypsys, Pfizer, IDEC Pharmaceuticals, and Schering-Plough Corporation.
  • from St. Bartholomew\'s Hospital College, University of London.\n"We are very pleased to welcome Dr. Grint as a member of the Board of Director\'s" said Sam Ellis, CEO of January Therapeutics.
  • Their initial development programs are focused in oncology, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors.\n'

WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order for Late Filing of Audited Annual Financial Statements

Wednesday, May 5, 2021 - 5:26pm

The Company required the MCTO as it was unable to file its Annual Filings within the deadline as required under National Instrument 51-102 \xe2\x80\x93 Continuous Disclosure Obligations (\xe2\x80\x9cNI 51-102\xe2\x80\x9d).

Key Points: 
  • The Company required the MCTO as it was unable to file its Annual Filings within the deadline as required under National Instrument 51-102 \xe2\x80\x93 Continuous Disclosure Obligations (\xe2\x80\x9cNI 51-102\xe2\x80\x9d).
  • WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage.
  • Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.
  • \xc2\xa0The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 31 countries in Europe and Asia, including Russia.\n'

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results

Tuesday, May 4, 2021 - 9:22pm

We also remain focused on realizing QINLOCK\xe2\x80\x99s potential in earlier lines of therapy,\xe2\x80\x9d said Steve Hoerter, President and Chief Executive Officer of Deciphera.

Key Points: 
  • We also remain focused on realizing QINLOCK\xe2\x80\x99s potential in earlier lines of therapy,\xe2\x80\x9d said Steve Hoerter, President and Chief Executive Officer of Deciphera.
  • Net product revenues for the first quarter of 2021 included U.S. sales of QINLOCK of $19.3 million and ex-U.S. sales of QINLOCK of $0.7 million.
  • In the first quarter of 2020, the Company did not generate product revenue.\nCost of Sales: Cost of sales were $0.2 million in the first quarter of 2021.
  • We explicitly disclaim any obligation to update any forward-looking statements.\nQINLOCK and the QINLOCK logo are registered trademarks, and Deciphera and the Deciphera logo are trademarks, of Deciphera Pharmaceuticals, LLC.\n'

Global Quantitative Structure-Activity Relationship Market Report 2021-2027 - Growing Adoption of QSAR and Artificial Intelligence in Drug Discovery - ResearchAndMarkets.com

Friday, April 30, 2021 - 3:24pm

However, low adoption rate of the technique in emerging countries is hindering the quantitative structure-activity relationship market growth.\nBased on application, the quantitative structure-activity relationship market is segmented into drug discovery, molecular modeling, chemical screening, regulatory and decision-making, and other applications.

Key Points: 
  • However, low adoption rate of the technique in emerging countries is hindering the quantitative structure-activity relationship market growth.\nBased on application, the quantitative structure-activity relationship market is segmented into drug discovery, molecular modeling, chemical screening, regulatory and decision-making, and other applications.
  • According to Lipinski\'s Rule of Five, the prediction of partition coefficient log P is an important measure used in identifying "drug likeness."
  • .\nQSARs have a substantial role in toxicity prediction, drug design, and environmental fate modeling of food & beverages, chemicals, and pharmaceuticals.
  • However, the high demand for promising tools for rapid and accurate drugs and vaccine development has boosted the demand for QSAR, thereby fueling the market growth.\n'

WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Thursday, April 29, 2021 - 1:55pm

The MCTO will be in effect until the Annual Filings are filed.

Key Points: 
  • The MCTO will be in effect until the Annual Filings are filed.
  • WPD has licensed in certain countries 10 novel drug candidates with 4 that are in clinical development stage.
  • Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.
  • \xc2\xa0The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes for most compounds 31 countries in Europe and Asia, including Russia.\n'